Trebananib (AMG 386): A Non-VEGF Antiangiogenesis Option in Women with Ovarian Cancer

Publisher： Bentham Science Publishers

E-ISSN： 2211-5536|3|4|193-202

ISSN： 2211-5528

Source： Current Angiogenesis, Vol.3, Iss.4, 2014-01, pp. : 193-202

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD)

By Giuseppe Loverro   Attilio Guarini   Edoardo Di Naro   Loredana Giacomantonio   Cristina Lavopa   Vincenzo Liso  

Hematology, Vol. 12, Iss. 2, 2007-04 ,pp. : 141-147

Maney Publishing

Access to resources Recommend Favorite

Cancer Cell Cannibalism: A Primeval Option to Survive.

By  

Current Molecular Medicine, Vol. 15, Iss. 9, 2015-11 ,pp. : 836-841

Bentham Science Publishers

Access to resources Recommend Favorite

Deguelin, a novel anti-tumorigenic agent targeting apoptosis, cell cycle arrest and anti-angiogenesis for cancer chemoprevention (Review)

By Wang   Ma   Zheng  

Molecular and Clinical Oncology, Vol. 1, Iss. 2, 2013-01 ,pp. : 215-219

Spandidos Publications

Access to resources Recommend Favorite

MUC1 in endometriosis and ovarian cancer

By Vlad Anda   Diaconu Iulia   Gantt Kira  

Immunologic Research, Vol. 36, Iss. 1-3, 2006-02 ,pp. : 229-236

Humana Press, Inc

Access to resources Recommend Favorite

Ovarian Cancer - Angiogenesis and Targeted Therapy

By  

Current Angiogenesis, Vol. 3, Iss. 4, 2014-01 ,pp. : 215-230

Bentham Science Publishers

Access to resources Recommend Favorite